stockrow
Friday 6 November 2026
Export WGS’s income statement to Excel — free account
GeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
62.46
1.90
−2.95%
Follow WGS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
979.45 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.71 | 8.71 | 4.26 | 4.49 | |
P/FCF ratio |
200.61 | 261.20 | 0.00 | 0.00 | |
P/Operating CF |
196.78 | (1,205.56) | (58.13) | (70.38) | |
P/B ratio |
10.62 | 12.09 | 7.41 | 8.35 | |
Price to Tangible BV |
29.03 | 29.52 | 17.52 | 20.15 | |
EV/Sales |
7.46 | 8.43 | 4.09 | 4.41 | |
EV/EBITDA |
88.56 | 296.54 | 0.00 | 0.00 | |
EV/Operating CF |
90.38 | 108.24 | (194.39) | (41.14) | |
EV/FCF |
193.92 | 252.56 | (63.17) | (26.44) | |
Quick Ratio |
2.47 | 2.26 | 2.83 | 2.90 | |
Current Ratio |
2.71 | 2.46 | 3.09 | 3.30 | |
Net Debt/EBITDA |
(32.11) | 16.74 | 1.46 | 3.32 | |
Debt/Assets |
10.44% | 9.20% | 19.11% | 20.11% | |
Debt/Equity |
0.18 | 0.16 | 0.38 | 0.40 | |
Asset Turnover |
0.89 | 0.91 | 0.93 | 0.96 | |
Operating CF/Net income |
(2.07) | 0.17 | 0.51 | 1.63 | |
Capex/Depreciation |
(0.95) | (0.63) | (0.95) | (1.51) | |
Interest Coverage |
(5.78) | — | (80.15) | (14.73) | |
Research and Development Expense of Revenue |
16.99% | 20.28% | 19.37% | 17.18% | |
Selling, General and Administrative Expense of Revenue |
58.20% | 61.13% | 72.95% | 66.44% | |
Intangible Assets out of Total Assets |
0.38 | 0.35 | 0.29 | 0.30 | |
Share Based Compensation of Revenue |
9.07% | 8.08% | 8.80% | 5.54% | |
Graham Net Nets |
0.01 | 0.01 | 0.01 | 0.00 | |
Graham Number |
5.01 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.10% | (0.56%) | (4.14%) | (5.30%) | |
Free Cash Flow Yield |
0.50% | 0.38% | (1.52%) | (3.72%) | |
Revenue per Share |
4.05 | 4.22 | 3.49 | 3.85 | |
Operating CF per Share |
0.55 | (0.11) | (1.10) | (0.98) | |
Capex per Share |
(0.21) | (0.15) | (0.22) | (0.34) | |
Free Cash Flow per Share |
0.33 | (0.26) | (1.32) | (1.32) | |
Cash per Share |
5.39 | 5.98 | 5.82 | 4.46 | |
Shareholders Equity per Share |
10.15 | 10.76 | 8.66 | 8.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.15 | 10.76 | 8.66 | 8.22 | |
Free Cash Flow |
9.60 | (7.44) | (38.86) | (39.09) | |
Working Capital |
149.96 | 159.38 | 182.99 | 171.73 | |
Capital Expenditures |
(6.17) | (4.35) | (6.45) | (10.11) | |
Net Current Asset Value |
35.94 | 52.76 | 18.45 | 9.10 | |
EV/EBIT |
301.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.04 | 0.06 | 0.09 | |
Price to Operating Income |
311.39 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
49.71 | 56.00 | 61.46 | 65.82 | |
Average Payables |
53.38 | 44.31 | 44.21 | 45.67 | |
Average Inventory |
10.67 | 12.30 | 12.45 | 14.88 | |
Average Assets |
451.37 | 471.55 | 476.37 | 472.67 | |
Average Common Equity |
248.38 | 276.71 | 255.76 | 260.68 |
Columns are period end dates · fundamentals updated 26 Oct 2026